AccessibilityHelpAbout Us
Chemomab Therapeutics logo

Chemomab Therapeutics(NASDAQ) CMMB

Market Cap$19.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-95%
1 Year-12%
1 Month+42%
$2.60
-3.35%
-0.09Today
Chemomab Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.692026-09-09
Chemomab Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.47%USD 2.732026-09-02
1 month+42.33%USD 1.892026-08-10
3 month+51.12%USD 1.782026-06-11
Year to date+63.03%USD 1.652025-12-31
1 year-11.8%USD 3.052025-09-09
3 year-34.39%USD 4.102023-09-08
5 year-95.21%USD 56.162021-09-10
Since inception-98.86%USD 236.002021-03-17

Chemomab Therapeutics Financials at a Glance

Market Cap

$19.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.60M

EPS (TTM)

-$1.02

P/E Ratio

-2.64

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$2.60

Volume

23,789

Open

$2.67

Previous Close

$2.60

Daily Range

$2.59 - $2.70

52-Week Range

$1.35 - $3.58

Estimated Earnings Date

Nov 6, 2026

CMMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology firm focused on developing innovative treatments for inflammatory and fibrotic conditions. The company's lead candidate, CM-101, is a humanized monoclonal antibody targeting the chemokine CCL24, currently being evaluated for primary sclerosing cholangitis and systemic sclerosis.

Products and Services
  • CM-101: A monoclonal antibody for inflammatory and fibrotic diseases
  • Research and development of novel therapies for chronic conditions
  • Clinical trials aimed at assessing drug efficacy and safety
Growth Outlook
  • Strong pipeline with CM-101 in advanced clinical trials
  • Potential market expansion in autoimmune disease treatments
  • Increased interest in innovative therapies for chronic conditions
Financial Highlights
  • Recent quarterly net income of -$2.2 million, reflecting ongoing R&D investments
  • Cash and short-term investments of approximately $6.7 million as of June 2026
  • Current ratio of 6.41, indicating strong liquidity position
Chemomab Therapeutics Ltd. operates in a promising sector, focusing on unmet medical needs in inflammatory and fibrotic diseases. The company's lead product, CM-101, has the potential to address significant market gaps, particularly in autoimmune conditions. With a solid financial foundation, including a robust cash position, Chemomab is well-positioned to advance its clinical programs and explore new opportunities in the biotechnology landscape. The ongoing commitment to research and development underscores the company's strategy to innovate and deliver effective therapies to patients.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Adi Mor, PhD

Website

www.chemomab.com

Headquarters

Tel Aviv-Yafo, TA 6158101, IL

CMMB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-70.81%

Return on Capital

-77.57%

Return on Assets

-74.25%

Earnings Yield

-37.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.25M

Volume

23.79K

Avg. Volume

151.04K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.96M

EBITDA

-$7.92M

Operating Cash Flow

-$11.22M

Capital Expenditure

-$3.03K

Free Cash Flow

-$11.22M

Cash & ST Invst.

$6.69M

Total Debt

$0.00

Chemomab Therapeutics Performance Analysis

Chemomab Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Chemomab Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Chemomab Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.68101.5%
20232023-12-31USD -8.22-15.0%
20242024-12-31USD -3.12-62.0%
20252025-12-31USD -1.42-54.5%
Chemomab Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3021.7%
Q42025-12-3114.9%
Q12026-03-318.3%
Q22026-06-30-27.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$19.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.62M

N/A

Employees

12

N/A

Net Income

-$2.20M

-7.1%

EBITDA

-$2.28M

-1.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.69M

-28.6%

Total Debt

$0.00

N/A

Accounts Receivable

$3.27M

+197.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-74.25%

N/A

Return on Invested Capital

-91.65%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KZIAKazia Therapeutics Ltd ADR
$11.01-7.32%
BIVIBioVie Inc.
$1.91-3.05%
GLMDGalmed Pharmaceuticals Ltd.
$4.63+21.05%
INMInMed Pharmaceuticals Inc.
$1.31+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TNONTenon Medical
$5.30+1.17%
SPCXSpace Exploration Technologies
$148.18+0.00%
NVDANvidia
$218.36-0.02%
INTCIntel
$100.32-0.06%

Questions About CMMB

What is the current price of Chemomab Therapeutics?

Chemomab Therapeutics is trading at $2.60 per share.

What is the 52-week range for Chemomab Therapeutics?

Over the past 52 weeks, Chemomab Therapeutics has traded between $1.35 and $3.58.

How much debt does Chemomab Therapeutics have?

As of the most recent reporting period, Chemomab Therapeutics reported total debt of $0.00.

How much cash does Chemomab Therapeutics have on hand?

Chemomab Therapeutics reported $6.00M in cash and cash equivalents in its most recent financial results.

What is Chemomab Therapeutics’s dividend yield?

Chemomab Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services